Market revenue in 2023 | USD 1,181.2 million |
Market revenue in 2030 | USD 806.1 million |
Growth rate | -5.3% (CAGR from 2023 to 2030) |
Largest segment | Hospitals |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care |
Key market players worldwide | Becton Dickinson & Co, BioMerieux SA, Bio-Rad Laboratories Inc, Abbott Laboratories, Agilent Technologies Inc, Danaher Corp, Hologic Inc, Illumina Inc, Grifols SA Ordinary Shares - Class A, Qiagen NV, Roche Holding AG, Siemens Healthineers AG ADR, Sysmex Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to molecular diagnostics market will help companies and investors design strategic landscapes.
Hospitals was the largest segment with a revenue share of 47% in 2023. Horizon Databook has segmented the Germany molecular diagnostics market based on hospitals, outpatient facilities, home care covering the revenue growth of each sub-segment from 2018 to 2030.
Germany holds a considerable share of Europe’s molecular diagnostics market, owing primarily to its large geriatric population. According to the UN’s population data, one in every 20 people in Germany is over 80 years, which is expected to increase to one in every six individuals by 2050.
Problems with the increasing geriatric population include a higher risk of chronic diseases, such as cardiovascular diseases, diabetes, and neurovascular disorders, due to the onset of senescence & decreased immunity levels. Rapid diagnostic techniques such as point-of-care molecular diagnostic devices are useful for this demographic.
Key manufacturers such as Roche and Bio-Rad are strengthening their operations in Germany, which is expected to boost the molecular diagnostics market. One of the major challenges for manufacturers is to procure reimbursements for new diagnostic tests. In some cases, establishing a new code and tariff for novel tests can take as long as 3 years.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Germany molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account